These stocks have promising assets in their portfolios that could help make their valuations soar in the future.

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Q: After getting a pacemaker, my 90-year-old mother was diagnosed with A-fib. She resisted taking a blood thinner for stroke risk but finally agreed. Not 90 minutes after the first pill, she had a ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

BERLIN, Nov 23 (Reuters) - German pharma company Bayer (BAYGn.DE), opens new tab reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the ...

DEAR DR. ROACH: I am struggling with a decision process due to a lack of consensus among various physicians. I was fortunate back in January at 66 years of age to survive bilateral pulmonary emboli ...

Texas Attorney General Ken Paxton speaks at the Austin Police Association in Austin, Texas, in September 2020. (Jay Janner/Austin American-Statesman via AP) MARSHALL, Texas (CN) — The makers of the ...

Shares of Bristol Myers Squibb (BMY) fell ~5% in the premarket on Friday after the company said that a Phase 3 trial for milvexian, an anticoagulant it is advancing with Johnson & Johnson (JNJ), is ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

A minimally invasive heart procedure to correct irregular heart rhythms called catheter ablation may reduce the risk of stroke enough that some patients can discontinue blood thinners, according to a ...

DEAR DR. ROACH: My husband was diagnosed with chronic lymphocytic leukemia (CLL) in 2010 and remained in stage 2 with no effects until 2022. In the interim, he was also diagnosed with atrial ...